Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
Phase 3 Trial for AZR-MD-001 in MGD Patients Begins
Azura Ophthalmics has reached a significant milestone with the enrollment of the first patient in the ASTRO study—a phase 3 clinical trial evaluating the efficacy and safety of AZR-MD-001 in patients grappling with clinical signs and symptoms of meibomian gland…
Novel Eyeglass Lens Tech Offers Relief for Migraine Patients
This spring, individuals grappling with migraines find relieve with a novel solution for managing light sensitivity, thanks to new eyeglass lens technology developed by a physician-scientist at the University of Utah John A. Moran Eye Center. The Impact of Migraine…
Zeiss Introduces Upgraded Cirrus 6000 OCT
Zeiss Medical Technology has introduced a series of enhancements to the Cirrus 6000, promising a more streamlined and data-centric workflow for ophthalmologists. This update boasts the largest OCT reference database in the US market and fortified cybersecurity features. With recent…
IND for DF-003 Cleared by FDA for ROSAH Syndrome Trial
In a significant development for the medical community, Drug Farm announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the Investigational New Drug (IND) application of DF-003. This novel drug, hailed as a first-in-class oral medication,…
USC Roski Eye Institute Investigates Promising Drugs for TED
The USC Roski Eye Institute is making significant strides in the realm of Thyroid Eye Disease (TED) treatment through pioneering clinical trials exploring new medications. TED, a condition characterized by bulging eyes and potential vision impairment, has traditionally necessitated multiple…
Tips for Choosing the Right Artificial Tears
Dry eyes can be an irritating and persistent problem for many individuals, leading to discomfort and potential vision issues if left untreated. Artificial tears are a common and effective solution for relieving dry eye symptoms. Dry eye is a common…
European Authorization Granted for Lytenava in Wet AMD
Outlook Therapeutics has achieved a significant milestone with the European Commission granting Marketing Authorization for Lytenava (bevacizumab gamma), an innovative ophthalmic formulation designed for the treatment of wet AMD (Age-related Macular Degeneration). This approval marks a pivotal moment as Lytenava…
Opthea Completes Enrollment in Wet AMD Phase 3 Trials
Opthea Limited announced the completion of enrollment in both the COAST and ShORe trials, constituting its pivotal Phase 3 clinical program. This program is designed to assess the safety and superior efficacy of sozinibercept in combination with standard-of-care anti-VEGF-A therapies…
Exonate Adds Dr. Rafiq Hasan to Leadership Team
Exonate announced the expansion of its Board with the appointment of Dr. Rafiq Hasan as Non-Executive Director. This strategic move aims to bolster the company’s expertise in ophthalmology, particularly within the diabetic eye disease sector, as it advances its lead…
Pegcetacoplan’s Role in Retinal Atrophy Treatment
Researchers from the National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital and University College London Institute of Ophthalmology, London have conducted a post hoc analysis of data from two phase 3 clinical trials of pegcetacoplan (Syfovre,…